QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds

QuidelOrtho Corp

2026-Q1 EPS reported -$1.35 revenue$619,800,000

Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
China distributor sales slow on proposed NHSA reimbursement cuts; EMEA orders delayed by Middle East conflict.
Q1 2026 free cash flow guided to negative $(65)-$(70)M; positive full-year still expected.
Low end of FY 2026 guidance remains achievable; full discussion on May 5 earnings call.
Core business (>70% of total rev) remains strong; cost actions underway to drive 2026 performance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

QuidelOrtho Corp reported first quarter of 2026, ended March 29, 2026 results: revenue $615-$620 million. Guidance reaffirmed.

Period: first quarter of 2026, ended March 29, 2026
Revenue: $615-$620 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 Revenue The Company currently expects preliminary unaudited revenue, as reported, of $615-$620 million for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down

View on SEC.gov

1347 earnings releases filed in the last 30 days. Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.